BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing Phase I clinical trial in patients with advanced solid tumors. We hypothesized...
Key Takeaways Manual pathology assessment is challenging and variable, limiting the data interpretation required for meaningful spatial biology analysis Unlike manual assessment, artificial intelligence and machine learning technologies analyze the complex...
Key Takeaways Classifying macrophages is important in understanding response to immunotherapy, but it may be challenging to do by eye Using an immunofluorescence-guided machine learning algorithm provided accurate macrophage classification This algorithm is useful in...
ABSTRACT In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor status including tumor immune landscape. PD-L1/PD-1 checkpoint therapies...
Key Takeaways Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue typesNEW YORK, NY and BROOMFIELD, CO — February 17, 2022 — Paige, the global leader in AI-based diagnostic software in pathology, and Flagship...
EVENTS
Meet with us at the Spatial Biology for Immuno-Oncology Summit.The Spatial Biology for Immuno-Oncology Summit is back for its second year, and Flagship Biosciences is a Program Partner for the event. Join us January 23-25 in San Diego where key industry leaders will...
Meet with us at the American Society of Hematology annual meeting in December. Whether you’re engaged in basic research or drug development, our genomics solutions offer valuable insights to help you achieve your goals. We offer the highest quality results and support...
Visit Flagship at SITC 2023 Booth #716. November 3-5, 2023. We offer a comprehensive set of discovery, translational and clinical testing, and assay development services to support your clinical studies in immune-oncology and immunotherapy. From the selection of...